| Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence P Perrot, J Rousseau, AL Bouffaut, F Rédini, E Cassagnau, ... PloS one 5 (6), e10999, 2010 | 126 | 2010 |
| Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients GA Odri, S Dumoucel, G Picarda, S Battaglia, F Lamoureux, N Corradini, ... Cancer research 70 (19), 7610-7619, 2010 | 88 | 2010 |
| 225Ac-H4py4pa for Targeted Alpha Therapy L Li, J Rousseau, MDG Jaraquemada-Pelaez, X Wang, A Robertson, ... Bioconjugate Chemistry 32 (7), 1348-1363, 2020 | 57 | 2020 |
| Therapeutic efficacy of soluble receptor activator of nuclear factor-κB-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma F Lamoureux, G Picarda, J Rousseau, C Gourden, S Battaglia, C Charrier, ... Molecular Cancer Therapeutics 7 (10), 3389-3398, 2008 | 51 | 2008 |
| p-NO2–Bn–H4neunpa and H4neunpa–Trastuzumab: Bifunctional Chelator for Radiometalpharmaceuticals and 111In Immuno-Single Photon Emission … S Spreckelmeyer, CF Ramogida, J Rousseau, K Arane, I Bratanovic, ... Bioconjugate Chemistry 28 (8), 2145-2159, 2017 | 48 | 2017 |
| Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models J Rousseau, V Escriou, F Lamoureux, R Brion, J Chesneau, S Battaglia, ... Journal of Bone and Mineral Research 26 (10), 2452-2462, 2011 | 47 | 2011 |
| Regulation of osteoprotegerin pro-or anti-tumoral activity by bone tumor microenvironment F Lamoureux, G Moriceau, G Picarda, J Rousseau, V Trichet, F Rédini Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1805 (1), 17-24, 2010 | 40 | 2010 |
| Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models J Rousseau, V Escriou, P Perrot, G Picarda, C Charrier, D Scherman, ... Cancer gene therapy 17 (6), 387-397, 2010 | 36 | 2010 |
| Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs C Miller, J Rousseau, CF Ramogida, A Celler, A Rahmim, CF Uribe Theranostics 12 (1), 232, 2022 | 35 | 2022 |
| Design, synthesis and evaluation of novel bifunctional tetrahydroxamate chelators for PET imaging of 89Zr-labeled antibodies J Rousseau, Z Zhang, GM Dias, C Zhang, N Colpo, F Benard, KS Lin Bioorganic & medicinal chemistry letters 27 (4), 708-712, 2017 | 33 | 2017 |
| A systematic review of molecular imaging agents targeting bradykinin B1 and B2 receptors J Lau, J Rousseau, D Kwon, F Bénard, KS Lin Pharmaceuticals 13 (8), 199, 2020 | 30 | 2020 |
| Allele-specific Col1a1 silencing reduces mutant collagen in fibroblasts from Brtl mouse, a model for classical osteogenesis imperfecta J Rousseau, R Gioia, P Layrolle, B Lieubeau, D Heymann, A Rossi, ... European Journal of Human Genetics 22 (5), 667-674, 2014 | 29 | 2014 |
| Evaluation of agonist and antagonist radioligands for somatostatin receptor imaging of breast cancer using positron emission tomography I Dude, Z Zhang, J Rousseau, N Hundal-Jabal, N Colpo, H Merkens, ... EJNMMI radiopharmacy and chemistry 2, 1-16, 2017 | 26 | 2017 |
| Evaluation of Met-Val-Lys as a Renal Brush Border Enzyme-Cleavable Linker to Reduce Kidney Uptake of 68Ga-Labeled DOTA-Conjugated Peptides and … S Bendre, Z Zhang, HT Kuo, J Rousseau, C Zhang, H Merkens, Á Roxin, ... Molecules 25 (17), 3854, 2020 | 20 | 2020 |
| Synthesis and evaluation of bifunctional tetrahydroxamate chelators for labeling antibodies with 89Zr for imaging with positron emission tomography J Rousseau, Z Zhang, X Wang, C Zhang, J Lau, E Rousseau, M Čolović, ... Bioorganic & Medicinal Chemistry Letters 28 (5), 899-905, 2018 | 20 | 2018 |
| Evaluation of the Tetrakis (3-Hydroxy-4-Pyridinone) Ligand THPN with Zirconium (IV): Thermodynamic Solution Studies, Bifunctionalization, and in Vivo Assessment of … C Buchwalder, MG Jaraquemada-Pelaez, J Rousseau, H Merkens, ... Inorganic Chemistry 58 (21), 14667-14681, 2019 | 18 | 2019 |
| 89Zr for antibody labeling and in vivo studies–a comparison between liquid and solid target production GM Dias, CF Ramogida, J Rousseau, NA Zacchia, C Hoehr, P Schaffer, ... Nuclear medicine and biology 58, 1-7, 2018 | 15 | 2018 |
| Novel anti-cancer strategy in bone tumors by targeting molecular and cellular modulators of bone resorption. B Brounais, C Ruiz, J Rousseau, F Lamoureux, F Blanchard, D Heymann, ... Recent Patents on Anti-Cancer Drug Discovery 3 (3), 178-186, 2008 | 13 | 2008 |
| Osteoblasts mineralization and collagen matrix are conserved upon specific Col1a2 silencing S Maruelli, R Besio, J Rousseau, N Garibaldi, J Amiaud, B Brulin, ... Matrix Biology Plus 6, 100028, 2020 | 11 | 2020 |
| Synthesis and evaluation of an 18F‐labeled trifluoroborate derivative of 2‐nitroimidazole for imaging tumor hypoxia with positron emission tomography PSG Nunes, Z Zhang, HT Kuo, C Zhang, J Rousseau, E Rousseau, J Lau, ... Journal of Labelled Compounds and Radiopharmaceuticals 61 (4), 370-379, 2018 | 11 | 2018 |
